TaiGen Biopharmaceuticals Holdings Limited (TPEX: 4157)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
12.45
-0.10 (-0.80%)
Nov 20, 2024, 12:29 PM CST
-16.16%
Market Cap 8.94B
Revenue (ttm) 148.75M
Net Income (ttm) 171.74M
Shares Out 717.84M
EPS (ttm) 0.24
PE Ratio 51.98
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 477,265
Open 12.50
Previous Close 12.55
Day's Range 12.35 - 12.55
52-Week Range 11.90 - 17.25
Beta 0.76
Analysts n/a
Price Target n/a
Earnings Date Nov 12, 2024

About TaiGen Biopharmaceuticals Holdings

TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. It is also developing Taigexyn for treating community-acquired pneumonia and diabetic foot infection, as well as other bacterial infections; Burixafor, a stem cell mobilizer for stem cell transplantation and chemosenzitization; TG-1000, an influenza antiviral drug for treating influenz... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Country Cayman Islands
Stock Exchange Taipei Exchange
Ticker Symbol 4157
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.